Precision Medicine in Oncology® | Specialty

The OncLive Precision Medicine in Oncology® condition center page is a comprehensive resource for clinical news and expert insights on precision-focused approaches in patients with cancer, with gene-targeted tyrosine kinase inhibitors and antibody-drug conjugates, checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and other tailored treatments. This page features news articles, interviews in written and video format, and podcasts that focus on updates and ongoing research with personalized therapies across solid and hematologic tumors.

Five Questions for Hans-Peter Gerber, PhD

July 10th 2012

Hans-Peter Gerber has been building a program to develop novel biotherapeutics for oncology, including antibody-drug conjugates, at the Pfizer Oncology Research Unit in Pearl River, New York.

Dr. Kris on the Combination of Targeted Therapies

July 6th 2012

Dr. Mark Kris, from Memorial Sloan-Kettering Cancer Center, on the Combination of Molecularly Targeted Therapies.

University of Chicago Comprehensive Cancer Center: Innovation in Research

July 6th 2012

For nearly 40 years, the University of Chicago Comprehensive Cancer Center has enjoyed a reputation for excellence and innovation.

Antibody-Drug Conjugates: Guided Missiles Deployed Against Cancerous Cells

July 5th 2012

Antibodies directed against tumor cell antigens or overexpressed proteins are currently the fastest-growing class of targeted cancer therapeutics.

Case-Based Discussion: Sequencing Prostate Cancer Therapy

July 3rd 2012

Case-based discussion on sequencing prostate cancer therapies for a 72-year-old man with a metastatic adenocarcinoma with small-cell components, a PSA score of 80, and a Gleason score of 10.

Diarrhea Less Severe With Molecularly Targeted Agents Than With Standard Chemotherapy

June 30th 2012

Recent evidence shows that some of the newer molecularly targeted therapies can cause diarrhea, which can lead to dose reductions and alterations.

Targeted Therapies Safer for Heart Than Anthracyclines

June 30th 2012

Although molecularly targeted agents can cause cardiac damage, it appears to be reversible and related to cellular dysfunction, as distinct from agents such as anthracyclines that cause cellular death and irreversible cardiac dysfunction.

Dr. Kirkman on the Combination of PX-866 and Docetaxel

June 27th 2012

Dr. Robert Kirkman, the CEO of Oncothyreon, on the Combination of PX-866 and Docetaxel

Dr. Hauschild Discusses the Dabrafenib BREAK-3 Trial

June 26th 2012

Dr. Axel Hauschild, from University Hospital, Schleswig-Holstein, Germany, Discusses the BREAK-3 Trial That Investigated the BRAF Inhibitor Dabrafenib.

Mutations Pass From Primary to Recurrent Endometrial Cancer

June 26th 2012

Most recurrent endometrial tumors have the same PI3K/Akt mutation profile as found in the primary tumor.

Unexpected Mutations Doom Therapy for Glioblastoma

June 25th 2012

Unexpected target mutations likely doomed a proven therapeutic approach to lung cancer in a test against glioblastoma.

Dr. Sandler Discusses the Tivantinib Mechanism of Action

June 25th 2012

Dr. Alan Sandler, from the Oregon Health & Science University, Discusses the Tivantinib Mechanism of Action

Targeting Non-Mutant EGFR: Genetic and Clinical Biomarkers May Help Validate Use of Inhibitors

June 25th 2012

A recent study suggests patients may be selected for therapy based on the number of EGFR gene copies, and evaluated for clinical benefit based on the severity of the rash that often develops.

Dr. Gandara on TS Expression in ALK-Positive NSCLC

June 19th 2012

Dr. David Gandara, from UC Davis Cancer Center, on Thymidylate Synthase Expression in ALK-Positive Non-small Cell Lung Cancer

Dr. Kris Discusses ASCO 2012 Lung Cancer Information

June 18th 2012

Dr. Mark Kris, from Memorial Sloan-Kettering Cancer Center, Discusses Lung Cancer Information Presented at the 2012 ASCO Annual Meeting.

Time Management: Balancing Clinical Education With Scientific Research

June 15th 2012

With careful attention to detail and conscientious efforts, clinical skills are likely to be transferable from clinical education to meeting research goals.

On the Horizon: Novel Inhibitors for Hematologic Malignancies

June 13th 2012

Increased understanding of the molecular mechanisms underlying the pathogenesis of hematologic cancers has led to the development of several promising new classes of targeted therapies.

JAK Pathway Yielding Results

June 13th 2012

JAK plays an important role in the formation and development of blood cells, and defects in the gene have been identified in myeloproliferative neoplasms.

Dr. Adjei on the Need for Targeted Therapy Education

June 12th 2012

Dr. Alex Adjei, from Roswell Park Cancer Institute, on the Need for Targeted Therapy Education

IPCC Case-Based Discussion: How Should We Sequence Therapy?

June 12th 2012

Three case studies focused on how best to sequence therapy in prostate cancer were presented by Daniel P. Petrylak, MD, and discussed by a panel that included Robert Dreicer, MD, and Oliver Sartor, MD.